BPC-157, TB-500 and GHK-Cu: reading recovery and anti-ageing claims
Peptide therapeutics include established medicines and compounds under investigation. Being a peptide, or acting in a cell or animal experiment, does not establish clinical benefit for an injected consumer product.
- Route / discussion scope
- Injectable claims reviewed; no administration protocol provided
- Conditions / goals discussed
- Injury recovery claims · Healthy-ageing claims
- BPC-157Recovery claims / evidence gap
Proposed biological effects do not establish a clinical recovery benefit.
FDA identifies limited safety information and immunogenicity concerns. Source ↗
- TB-500 / thymosin beta-4 fragmentRecovery claims / evidence gap
Research terminology does not establish an approved recovery treatment.
Identity, impurities and route-specific evidence need scrutiny. Source ↗
- Injectable GHK-CuSkin/anti-ageing claims / evidence gap
Topical or mechanistic findings cannot establish injectable benefit.
Human safety data are limited for injected products. Source ↗
For injury recovery, skin health or healthy ageing, ask for human outcomes relevant to the exact claim, not mechanisms alone. This is an evidence-review topic, not a treatment recommendation or a purchasing directory.